Search results for "Amines"

showing 10 items of 664 documents

Comparing asthma treatment in elderly versus younger patients

2011

SummaryA randomised 6-month study compared two maintenance doses of budesonide/formoterol (Symbicort® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2 and 2 × 2, in 8053 asthmatics with symptoms despite treatment with inhaled corticosteroids ± inhaled long-acting β2-agonists. This analysis compared response to the two treatments in elderly patients, ≥65 years, with that in younger patients. Elderly patients with early- or late-onset asthma were also compared.Elderly patients had lower post-bronchodilator FEV1 percentage predicted normal at base…

AdultMalePulmonary and Respiratory MedicineBudesonideSymbicort SMARTmedicine.medical_specialtylaw.inventionExacerbationsElderlyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansBudesonideBudesonide/formoterolAgedAsthmaACQDose-Response Relationship Drugbusiness.industryHazard ratiomedicine.diseaseConfidence intervalAsthmaBronchodilator AgentsSurgeryTreatment OutcomeBudesonide/formoterolEthanolaminesAsthma Control QuestionnaireDisease ProgressionQuality of LifeDrug Therapy CombinationFemaleFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed mai…

2004

Asthma guidelines suggest a stepwise approach to maintenance pharmacological treatment of persistent asthma until control is attained, and a 3 month review of the fixed maintenance dosing for step-up or step-down adjustment. This 12-week study compared the efficacy and safety of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler 160/4.5 or 80/4.5 microg) given as adjustable maintenance or fixed maintenance dosing. Patients (n = 2358) were randomised to budesonide/formoterol fixed maintenance dosing (two inhalations bid) or adjustable maintenance dosing (two inhalation bid; stepping up to four inhalations bid if asthma worsened for a maximum of 14 days; stepping down to two inha…

AdultMalePulmonary and Respiratory MedicineBudesonidemedicine.drug_classDrug Administration ScheduleFormoterol FumarateBronchodilatormedicineHumansPharmacology (medical)DosingBudesonideathma; therapy; guidelinesAsthmaDose-Response Relationship DrugInhalationbusiness.industryNebulizers and VaporizersInhalerBiochemistry (medical)medicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDrug Therapy CombinationFemaleFormoterolbusinessmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Effects of Inhaled Fenoterol on the Circadian Rhythm of Expiratory Flow in Allergic Bronchial Asthma

1983

Metered-dose aerosol treatment with fenoterol for three consecutive days, in eight patients suffering from allergic asthma, caused the disappearance of FEV1 and MEF50 circadian rhythm. We attribute such behavior to the suppression of the bronchomotor tone induced by fenoterol. The administration on different days of a single dose of fenoterol aerosol in another group of eight patients pointed out the variability of the effects of the drug at different hours of the day. We believe the results obtained are important for a better dosage and time distribution of the therapy with beta2 agonists.

AdultMalePulmonary and Respiratory MedicineTime distributionMaximal Midexpiratory Flow RateCritical Care and Intensive Care MedicinemedicineHumansCircadian rhythmFenoterolFenoterolAsthmaAerosolsbusiness.industryAllergic asthmaForced Expiratory Flow RatesMaximal midexpiratory flow raterespiratory systemmedicine.diseaseAsthmaCircadian RhythmForced Expiratory Flow RatesB2 receptorEthanolaminesAnesthesiaFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Preference for Rizatriptan 10-mg Wafer vs. Eletriptan 40-mg Tablet for Acute Treatment of Migraine

2006

Preference is a composite, patient-oriented endpoint incorporating efficacy, tolerability, formulation, and convenience of medications. The objective of this study was to compare patient preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. In this multicentre, open-label, two-period, crossover study, out-patients were randomly assigned to treat the first of two moderate to severe migraines with rizatriptan or eletriptan and the second with the alternate therapy. Patients completed diary assessments at baseline and up to 24 h after taking study medication. At the last visit, patients completed a psychometrically validated preference questionnai…

AdultMalePyrrolidinesTime FactorsAdolescentMigraine DisordersAdministration OralTriptanslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumans030212 general & internal medicineEletriptanAgedbusiness.industryGeneral MedicineMiddle AgedTriazolesmedicine.diseaseCrossover studyRizatriptanTryptaminesConfidence intervalSerotonin Receptor AgonistsMigraineTolerabilityPatient SatisfactionAnesthesiaFemaleNeurology (clinical)business030217 neurology & neurosurgeryTabletsmedicine.drugCephalalgia
researchProduct

Effects of Water Immersion Methods on Postexercise Recovery of Physical and Mental Performance.

2019

Ahokas, EK, Ihalainen, JK, Kyrolainen, H, and Mero, AA. Effects of water immersion methods on postexercise recovery of physical and mental performance. J Strength Cond Res 33(6): 1488-1495, 2019-The aim of this study was to compare the effectiveness of 3 water immersion interventions performed after active recovery compared with active recovery only on physical and mental performance measures and physiological responses. The subjects were physically active men (age 20-35 years, mean ± SD 26 ± 3.7 years). All subjects performed a short-term exercise protocol, including maximal jumps and sprinting. Four different recovery methods (10 minutes) were used in random order: cold water immersion (C…

AdultMaleRelaxationTime FactorsHydrocortisonePhysical Therapy Sports Therapy and Rehabilitation030204 cardiovascular system & hematologyAthletic PerformanceRunningRandom order03 medical and health sciencesRandom AllocationYoung Adult0302 clinical medicineCatecholaminesHeart RateSurveys and QuestionnairesHeart rateImmersionMedicineHumansOrthopedics and Sports MedicineTestosteroneLactic AcidExercise physiologyCreatine KinaseExerciseHydrotherapybiologyRelaxation (psychology)business.industryWater030229 sport sciencesGeneral MedicineMyalgiaRecovery of FunctionRunning timeBicyclingCold TemperatureSprintWater immersionAnesthesiabiology.proteinExercise TestCreatine kinasePerceptionbusinessJournal of strength and conditioning research
researchProduct

[Validity of the use of penbutolol in essential arterial hypertension].

1990

Thirty patients suffering from WHO I-II class slight-moderate essential arterial hypertension were treated with a beta-blocker (Penbutolol) alone and once a day to assess its antihypertensive effectiveness and its affect on heart frequency, lipid metabolism and kidney function. The drug proved highly effective in reducing P.A.S. and P.A.D. values and no negative influence was documented on lipid metabolism, kidney function or heart frequency.

AdultMaleSettore MED/09 - Medicina InternaAdult Aged Blood Pressure/drug effects Diastole Drug Evaluation Female Humans Hypertension/drug therapy* Male Middle Aged Penbutolol/therapeutic use* Propanolamines/therapeutic use* Systole SubstancesSystoleBlood PressureMiddle AgedSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolarePropanolaminesDiastoleHypertensionDrug EvaluationHumansFemalePenbutololAgedMinerva medica
researchProduct

Blood pressure changes after automatic and fixed CPAP in obstructive sleep apnea. Relationship with nocturnal sympathetic activity.

2011

Treatment of obstructive sleep apnea (OSA) by continuous positive airway pressure (CPAP) usually causes a reduction in blood pressure (BP), but several factors may interfere with its effects. In addition, although a high sympathetic activity is considered a major contributor to increased BP in OSA, a relationship between changes in BP and in sympathetic nervous system activity after OSA treatment is uncertain. This study was undertaken to assess if, in OSA subjects under no pharmacologic treatment, treatment by CPAP applied at variable levels by an automatic device (APAP) may be followed by a BP reduction, and if that treatment is associated with parallel changes in BP and catecholamine exc…

AdultMaleSympathetic nervous systemSympathetic Nervous SystemAmbulatory blood pressurePhysiologymedicine.medical_treatmentambulatory blood pressure monitoring catecholaminesBlood PressureSettore MED/10 - Malattie Dell'Apparato RespiratorioNorepinephrineCatecholaminesInternal MedicinemedicineHumansContinuous positive airway pressureWakefulnessSleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industrySleep apneaGeneral MedicineBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseCircadian RhythmNormetanephrinenervous system diseasesrespiratory tract diseasesObstructive sleep apneamedicine.anatomical_structureBlood pressureAnesthesiaAmbulatoryCatecholamineSleepbusinessmedicine.drug
researchProduct

Interaction of atenolol with furosemide and calcium and aluminum salts

1981

Six healthy subjects were treated with 100 mg atenolol. After a therapy-free interval of 4 wk the same subjects received the same dose of atenolol with furosemide, 40 mg, with calcium (as the lactate gluconate and carbonate), 500 mg, or with aluminum hydroxide, 5.6 gm. Atenolol alone and in combination was administered first as a single oral dose; a long-term 6-day treatment began 48 hr later. Addition of furosemide did not influence atenolol kinetics, but aluminum hydroxide led to an insignificant reduction (P greater than 0.05) of mean peak plasma levels of about 20% and of the area under the plasma concentration-time curve (AUC -infinity) from 5818 to 4353 ng ml-1 hr (P greater than 0.05…

AdultMaleTachycardiamedicine.medical_specialtyPhysical Exertionchemistry.chemical_elementBlood PressureCalciumPharmacologyPropanolaminesFurosemideHeart RateInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)PharmacologyHealthy subjectsFurosemideAluminum saltsMiddle AgedAtenololKineticsPeak plasmaEndocrinologyBlood pressureAtenololchemistryHypertensionCalciumFemalemedicine.symptomAluminumcirculatory and respiratory physiologymedicine.drugClinical Pharmacology and Therapeutics
researchProduct

Life context of pharmacological academic performance enhancement among university students – a qualitative approach

2014

Background Academic performance enhancement or cognitive enhancement (CE) via stimulant drug use has received increasing attention. The question remains, however, whether CE solely represents the use of drugs for achieving better academic or workplace results or whether CE also serves various other purposes. The aim of this study was to put the phenomenon of pharmacological academic performance enhancement via prescription and illicit (psycho-) stimulant use (Amphetamines, Methylphenidate) among university students into a broader context. Specifically, we wanted to further understand students’ experiences, the effects of use on students and other factors, such as pressure to perform in thei…

AdultMaleUniversitiesSubstance-Related Disorders610 MedizinStimulantsHealth(social science)Cognition610 Medical sciencesHumansStudentsNootropic AgentsQualitative ResearchLife impactEthicsMotivationHealth PolicyAmphetaminesUniversity studentsIssues ethics and legal aspectsAttitudesAcademic performance enhancementMethylphenidateEducational StatusCentral Nervous System StimulantsFemaleResearch ArticleCognitive enhancementBMC Medical Ethics
researchProduct

The Effects of an Essential Oil and an Amine Fluoride/Stannous Fluoride Mouthrinse on Supragingival Plaque Regrowth

2008

Background: The side effects of chlorhexidine (CHX) have stimulated the search for alternative antiplaque agents such as amine fluoride/stannous fluoride (ASF) and essential oils (EO). The aim of the study was to investigate the plaqueinhibiting effects of two commercially available mouthrinses containing ASF and EO, respectively. Methods: The study was an observer-masked, randomized, 5 · 5 Latin square cross-over design, balanced for carryover effects, involving 15 volunteers in a 4-day plaque regrowth model. A 0.12% CHX rinse and a saline solution served as positive and negative controls, respectively. On day 1, subjects received professional prophylaxis, suspended oral hygiene measures, …

AdultMalefluoride/therapeutic useDosemedicine.medical_treatmentDental PlaqueMouthwashesPainDentistryDental plaqueOral hygienelaw.inventionTaste Disorderschemistry.chemical_compoundSettore MED/28 - Malattie OdontostomatologichelawLatin squareDental plaque/prevention and controlOils VolatilemedicineHumansSingle-Blind MethodAminesSalineEssential oilCross-Over StudiesTerpenesbusiness.industryChlorhexidineDental Plaque IndexChlorhexidineessential oils/ therapeutic useoral hygienemedicine.diseaseSalicylatesDrug CombinationschemistryAnti-Infective Agents LocalTin FluoridesPeriodonticsFemaleMouth DiseasesbusinessFluoridemedicine.drugJournal of Periodontology
researchProduct